Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Microsatellite Instability 1Melanoma 1Colorectal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

bintrafusp alfa protein, human 1Triamcinolone Acetonide 1TH 302 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Injections, Intramuscular 1ALT-803 1AGN 194204 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration Resistant Prostate Cancer × ALT-803 × Genitourinary × Clear all
NCT05445882 2024-04-02

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Genitourinary

Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡